← Back to Clinical Trials
Recruiting NCT03117010

Prospective Cohort for Adult Hemophagocytosis

Trial Parameters

Condition Hemophagocytic Lymphohistiocytoses
Sponsor Samsung Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 81
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2017-01-01
Completion 2025-12-31
Interventions
SteroidsEtoposide

Brief Summary

This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.

Eligibility Criteria

Inclusion Criteria: * Subjects should fulfill the following criteria 1. Subjects should have at least one of the following problems 1. Presence of hemophagocytosis in tissue or bone marrow 2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria 2. Age \> 18 years 3. Written informed consents Exclusion Criteria: * Subjects cannot satisfy the inclusion criteria

Related Trials